Department of Pharmacy, Kerala University of Health Sciences, Thrissur, Kerala, India.
Department of Pharmaceutics, Amrita School of Pharmacy, Amrita Vishwa Vidyapeetham, AIMS Health Sciences Campus, Kochi-682 041, India.
Comb Chem High Throughput Screen. 2022;25(5):763-767. doi: 10.2174/1386207324666210805121828.
SARS-CoV-2, the novel coronavirus and the causative organism of the Covid-19 pandemic wreaked havoc worldwide producing asymptomatic to symptomatic cases leading to significant morbidity and mortality even after infection. Most of the countries reported a mortality rate of 2-3 % majorly due to cardiorespiratory failures. Recent studies highlighted the neurological involvement playing a key role in cardiorespiratory failures and other symptoms such as headache, anosmia, and ageusia observed in Covid-19 patients. Studies suggest SARS-CoV-2 entry via Olfactory Epithelium (OE), and the expression of type 2 transmembrane serine protease (TMPRSS2) in addition to Angiotensin-Converting Enzyme 2 (ACE2) can facilitate SARS-CoV-2 neurotropism. The virus can either travel via peripheral blood vessel causing endothelial dysfunction, triggering coagulation cascade and multiple organ dysfunction or reach the systemic circulation and take a different route to the Blood-Brain Barrier (BBB), disrupting the BBB causing neuroinflammation or neuronal excitotoxicity resulting in the development of encephalitis, encephalopathy, seizures, and strokes. SARS-CoV-2 invasion on the brain stem is believed to be responsible for the cardiorespiratory failures observed in Covid-19 patients. Apart from viral invasion via hematogenous route, SARS-CoV-2 neural invasion via PNS nerve terminal, results in viral replication and retrograde transportation to soma leading to invasion of the CNS including the brain producing neurological manifestations of the disease either in the initial stages or during the course of the disease and even for a long period post-infection in many cases. The ACE2 receptors are expressed in the brain and glial cells and SARS-CoV-2 acts via neuronal as well as nonneuronal pathways. But the exact cell types involved and how they can trigger inflammatory pathways need further in-depth study for the development of targeted therapy.
新型冠状病毒(SARS-CoV-2)是引发 COVID-19 大流行的新型冠状病毒,也是导致 COVID-19 的病原体。它在全球范围内造成了严重破坏,引发了从无症状到有症状的感染,导致了大量的发病率和死亡率。大多数国家报告的死亡率为 2-3%,主要是由于心肺衰竭。最近的研究强调了神经系统的参与在心肺衰竭和其他症状(如头痛、嗅觉丧失和味觉丧失)中起着关键作用,这些症状在 COVID-19 患者中观察到。研究表明,SARS-CoV-2 通过嗅觉上皮(OE)进入,以及 2 型跨膜丝氨酸蛋白酶(TMPRSS2)的表达除了血管紧张素转换酶 2(ACE2)外,还可以促进 SARS-CoV-2 的神经嗜性。病毒可以通过外周血管传播,导致内皮功能障碍,引发凝血级联反应和多器官功能障碍,也可以进入全身循环,通过不同途径到达血脑屏障(BBB),破坏 BBB 导致神经炎症或神经元兴奋毒性,从而导致脑炎、脑病、癫痫发作和中风的发生。SARS-CoV-2 对脑干的侵袭被认为是 COVID-19 患者心肺衰竭的原因。除了通过血液途径的病毒入侵外,SARS-CoV-2 通过周围神经系统神经末梢的神经入侵,导致病毒复制和逆行运输到体部,导致中枢神经系统(包括大脑)的入侵,导致疾病的神经系统表现,无论是在疾病的初始阶段还是在疾病过程中,甚至在感染后很长一段时间,在许多情况下都是如此。ACE2 受体在大脑和神经胶质细胞中表达,SARS-CoV-2 通过神经元和非神经元途径发挥作用。但确切的涉及细胞类型以及它们如何引发炎症途径需要进一步深入研究,以开发靶向治疗。